Peter Lynch · Growth at a reasonable price (GARP)
Is Arbutus Biopharma Corporation (ABUS) a Peter Lynch Stock?
Some GARP characteristics, but growth or valuation is stretched.
48/100
No encaja
2/6 criterios cumplidos
Los criterios de Peter Lynch, aplicados a ABUS
PEG ≤ 1.0
clave-
EPS CAGR ≥ 15%
clave-
Revenue CAGR ≥ 10%
6.4%
Net margin > 0
84.0%
Cómo se valora ABUS en otras estrategias
Datos financieros en vivo
Cap. mercado
$682.08M
PER (TTM)
5.1x
ROIC (TTM)
56.72%
Margen bruto
99.98%
Otros análisis Peter Lynch
Preguntas frecuentes
What is ABUS's Peter Lynch fit score?
ABUS scores 48/100 on our Peter Lynch fit engine. Some GARP characteristics, but growth or valuation is stretched.
Does Peter Lynch actually own ABUS?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends ABUS.
How often is this score updated?
ABUS's Peter Lynch fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Herramienta educativa, no es asesoramiento financiero. Las puntuaciones se calculan a partir de datos financieros públicos contra los criterios publicados de cada estrategia de inversión. No afirmamos que Peter Lynch posea o recomiende ABUS personalmente.
